Physician profile
Aaron King
NPI 1568571750
$1,118,722.95
in general payments reported to CMS, 2019-2025
44 companies · $290K in 2025
The $290K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108K · 2020: $78K · 2021: $129K · 2022: $183K · 2023: $171K · 2024: $160K · 2025: $290K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $319K · Consulting Fee: $106K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $102K · Travel and Lodging: $57K · Food and Beverage: $36K · Education: $63.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $318,884.02 |
| Consulting Fee | $106,122.43 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $102,082.75 |
| Travel and Lodging | $56,747.65 |
| Food and Beverage | $36,237.00 |
| Education | $63.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $527,952.07 | 2019-2025 | Ozempic, Rybelsus, Victoza |
| Lilly USA, LLC | $253,754.43 | 2020-2025 | Mounjaro, Jardiance, Baqsimi |
| Dexcom, INC. | $141,210.33 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Abbott Laboratories | $111,363.55 | 2021-2025 | Freestyle Libre 3, Afinion 2, Afinion Hba1c Dx |
| Astellas Pharma US INC | $16,446.13 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $15,869.66 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $15,081.81 | 2019-2022 | |
| Mannkind Corporation | $12,576.97 | 2019-2023 | Afrezza |
| Eli Lilly and Company | $10,275.77 | 2023-2025 | |
| Medtronic Minimed, INC. | $8,644.28 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,033.49 | 2021-2025 | |
| Novo Nordisk As | $750.00 | 2023 | |
| Xeris Pharmaceuticals, INC. | $583.11 | 2021-2024 | Recorlev |
| Corcept Therapeutics | $530.12 | 2023-2025 | Korlym |
| Beta Bionics, INC. | $373.03 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.